Understanding Anaphylaxis: The Complete Guide
Last reviewed: March 2026
What Is Anaphylaxis?
Anaphylaxis is a severe, rapid-onset, systemic allergic reaction that can be fatal if not treated promptly. It occurs when the immune system massively overreacts to an allergen, releasing a flood of chemicals from immune cells (primarily mast cells and basophils) throughout the body. In food allergy, the mechanism is typically IgE-mediated: the immune system has previously produced IgE antibodies specific to a food protein, and upon re-exposure, those antibodies trigger mast cells to release histamine, leukotrienes, prostaglandins, and other inflammatory mediators. This chemical cascade affects multiple organ systems simultaneously, causing symptoms that can progress from uncomfortable to life-threatening within minutes. Food is the most common trigger of anaphylaxis in children and adolescents, while medications and insect stings are more common triggers in adults. Among food triggers, peanuts, tree nuts, milk, eggs, fish, shellfish, wheat, soy, and sesame account for the vast majority of cases, though any food can theoretically cause anaphylaxis. Anaphylaxis is not rare: it is estimated to occur in 1 to 2 percent of the general population over a lifetime, and its incidence has been increasing over the past two decades.
Symptoms by Body System
Anaphylaxis affects multiple body systems, and understanding how symptoms manifest in each system helps with rapid recognition. Skin and mucosal symptoms (present in up to 90% of anaphylaxis cases) include hives (urticaria), flushing, itching, swelling (angioedema) of the face, lips, tongue, and throat, and warmth. Respiratory symptoms (present in up to 70% of cases) include shortness of breath, wheezing, coughing, chest tightness, nasal congestion, sneezing, voice changes (hoarseness), difficulty swallowing, and stridor (a high-pitched breathing sound indicating upper airway narrowing). Cardiovascular symptoms (present in up to 45% of cases) include a drop in blood pressure (hypotension), rapid or weak pulse, dizziness, lightheadedness, fainting (syncope), and pale or blue skin (cyanosis). In severe cases, cardiovascular collapse can lead to cardiac arrest. Gastrointestinal symptoms (present in up to 45% of cases) include nausea, vomiting, abdominal cramping, and diarrhea. Neurological symptoms include anxiety, a sense of impending doom (patients often describe "feeling like something terrible is about to happen"), confusion, and loss of consciousness. Critically, skin symptoms may be absent in up to 10 to 20 percent of anaphylaxis cases, which can delay recognition. Any combination of symptoms involving two or more body systems after exposure to a known or suspected allergen should be treated as anaphylaxis.
Biphasic Anaphylaxis
Biphasic anaphylaxis refers to a recurrence of anaphylaxis symptoms after the initial reaction has apparently resolved, without additional exposure to the allergen. The second phase typically occurs within 1 to 12 hours after the initial reaction resolves, though cases up to 72 hours later have been documented. The prevalence of biphasic reactions varies in the literature, with estimates ranging from 5 to 20 percent of anaphylaxis episodes. The second reaction can be milder than, equal to, or more severe than the initial episode, and it requires the same treatment (epinephrine and emergency medical care). Several risk factors have been associated with biphasic reactions: severe initial reactions, delayed epinephrine administration, the need for more than one dose of epinephrine during the initial reaction, and a history of previous biphasic reactions. The unpredictability of biphasic reactions is the primary reason why current guidelines recommend that all patients with anaphylaxis be observed in a medical facility for a minimum of 4 to 6 hours after the resolution of symptoms. Some allergists recommend longer observation periods (8 to 12 hours) for patients with severe initial reactions or known risk factors for biphasic reactions. Patients should be sent home with an epinephrine auto-injector and instructions to return to the emergency department if symptoms recur.
Exercise-Induced Anaphylaxis and Cofactors
Exercise-induced anaphylaxis (EIA) is a condition where physical activity triggers anaphylaxis. In some cases, it occurs only when exercise follows ingestion of a specific food within a certain time window, typically 2 to 6 hours. This is called food-dependent exercise-induced anaphylaxis (FDEIA). The most commonly implicated foods include wheat, shellfish, celery, and tomatoes, though any food can be involved. The person may be able to eat the food without exercise or exercise without eating the food, and only the combination triggers the reaction. Beyond exercise, several other cofactors can lower the threshold for anaphylaxis, making a reaction more likely or more severe. These include alcohol consumption (which increases intestinal permeability and may enhance allergen absorption), non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and aspirin, acute infections or illness, emotional stress, sleep deprivation, menstruation (in some women), and extreme temperatures (hot baths, saunas). Understanding these cofactors is important because they help explain why the same person can eat the same amount of the same allergen and react severely one time while having only mild symptoms another time. If you have experienced anaphylaxis and exercise, alcohol, or NSAIDs were involved, discuss these cofactors specifically with your allergist.
How Epinephrine Works
Epinephrine (adrenaline) is the first-line, life-saving treatment for anaphylaxis. Understanding how it works can help you appreciate why it is so critical and why no other medication can substitute for it during a severe reaction. Epinephrine acts on multiple receptor types throughout the body. On alpha-1 adrenergic receptors, it causes vasoconstriction (tightening of blood vessels), which counteracts the dangerous drop in blood pressure that occurs during anaphylaxis and reduces swelling by decreasing fluid leakage from blood vessels. On beta-1 adrenergic receptors, it increases the heart rate and the force of cardiac contractions, improving blood flow and cardiac output. On beta-2 adrenergic receptors, it relaxes bronchial smooth muscle (opening the airways), which directly addresses the breathing difficulty that is one of the most dangerous aspects of anaphylaxis. Epinephrine also inhibits further release of inflammatory mediators from mast cells and basophils, helping to halt the progression of the allergic cascade. It begins working within minutes of injection, though its effects last only 15 to 20 minutes. This is why calling 911 after administering epinephrine is essential: the patient needs ongoing medical monitoring and may need additional doses, IV fluids, corticosteroids, and other supportive care. No other medication provides this combination of effects. Antihistamines do not raise blood pressure, open airways, or stimulate the heart.
When to Administer Epinephrine
The decision to administer epinephrine should be made quickly. Current guidelines from NIAID, FARE, ACAAI, and AAAAI all emphasize: when in doubt, give epinephrine. The risks of administering epinephrine when it is not strictly needed (temporary increase in heart rate, jitteriness, headache, pallor) are far less dangerous than the risks of withholding epinephrine during true anaphylaxis (airway closure, cardiovascular collapse, death). Administer epinephrine immediately if: the person has known or suspected exposure to an allergen AND has symptoms involving two or more body systems (for example, hives plus vomiting, or throat tightness plus dizziness); or the person has known or suspected exposure to an allergen AND has any single severe symptom (difficulty breathing, throat swelling, loss of consciousness, severe drop in blood pressure). Some allergists also recommend using epinephrine for a single mild symptom if the patient has a history of severe or rapidly progressing reactions, because past reactions do not reliably predict the severity of future reactions. Do not wait to see if antihistamines work. Do not wait for symptoms to "get bad enough." Do not wait to arrive at the hospital. Inject epinephrine, call 911, and position the patient appropriately. Every minute of delay in epinephrine administration is associated with worse outcomes.
Auto-Injector Comparison: EpiPen, Auvi-Q, and Generic
Three main epinephrine auto-injector options are available in the United States, each with distinct features. EpiPen is the most widely recognized brand. It comes in two doses: EpiPen Jr. (0.15 mg for patients 33 to 66 pounds) and EpiPen (0.3 mg for patients over 66 pounds). The injection mechanism involves removing a blue safety cap and pressing the orange tip firmly against the outer thigh. EpiPen has a relatively long needle (which can be a consideration for very young or very thin patients) and the device should be held in place for 10 seconds. Auvi-Q is a compact, wallet-sized device with a unique feature: built-in voice instructions that guide the user through each step of the injection process. This can be invaluable during the stress and confusion of an emergency. Auvi-Q comes in three doses: 0.1 mg, 0.15 mg, and 0.3 mg. The manufacturer offers a direct-to-patient program that provides the device at no cost for many commercially insured patients. Generic epinephrine auto-injectors, including authorized generics of EpiPen and products from manufacturers like Teva, are typically less expensive than brand-name options and contain the same medication at the same doses. The injection mechanism is similar to EpiPen. Cost is a significant consideration: without insurance, brand-name auto-injectors can cost several hundred dollars for a two-pack. Generic options, manufacturer assistance programs, and pharmacy discount cards can help reduce costs. Regardless of which device you choose, practice with the trainer device regularly and check expiration dates monthly.
Hospital Protocol After Epinephrine
After epinephrine is administered and 911 is called, the patient should be transported to an emergency department even if symptoms have improved. In the hospital, the medical team will assess the severity of the reaction, monitor vital signs, and provide additional treatment as needed. Standard hospital protocol for anaphylaxis includes continuous monitoring of blood pressure, heart rate, oxygen saturation, and respiratory status. Additional medications may be given: a second dose of epinephrine if symptoms persist or recur, IV fluids to support blood pressure, inhaled bronchodilators (albuterol) for persistent wheezing, H1 antihistamines (diphenhydramine) and H2 antihistamines (famotidine) for ongoing hives and itching, and systemic corticosteroids (methylprednisolone or prednisone), which may help prevent or reduce the severity of biphasic reactions, though their benefit in this context is debated. The patient should be observed for a minimum of 4 to 6 hours, and many emergency departments will observe for longer if the initial reaction was severe. Upon discharge, the patient should receive a prescription for epinephrine auto-injectors (if they do not already have one), instructions to follow up with an allergist, and education about biphasic reactions and when to return to the emergency department.
Anaphylaxis Action Plans
An anaphylaxis action plan (also called an emergency action plan or allergy action plan) is a written document that outlines how to recognize and respond to an allergic reaction, step by step. Every person at risk of anaphylaxis should have one, developed in collaboration with their allergist. A comprehensive action plan includes: the patient's name, photo, date of birth, and weight; a list of confirmed allergens; the specific epinephrine device prescribed and its dose; a clear description of mild symptoms (single-system involvement: isolated hives, mild stomach discomfort, mild nasal congestion) with instructions to administer antihistamines and monitor closely; a clear description of severe symptoms (multi-system involvement or any single life-threatening symptom) with instructions to administer epinephrine immediately and call 911; positioning instructions (lie down with legs elevated unless vomiting or having difficulty breathing); emergency contact numbers; and the location of emergency medications. FARE provides a widely used, allergist-endorsed action plan template that can be downloaded for free. The plan should be reviewed and updated annually or whenever there is a change in the patient's allergy status, weight, or prescribed medications. Copies should be kept everywhere the person spends time: home, school, work, grandparents' house, camp, and with babysitters and coaches.
Prevalence, Fatality Statistics, and Risk Factors
Anaphylaxis is more common than many people realize. In the United States, anaphylaxis occurs in an estimated 1.6 to 5.1 percent of the population over a lifetime. Food-induced anaphylaxis results in approximately 30,000 emergency department visits per year in the US and an estimated 150 to 200 deaths annually, though exact figures are difficult to determine because anaphylaxis is underreported as a cause of death. The incidence of anaphylaxis has been increasing over the past 20 years, paralleling the overall increase in food allergy prevalence. Several risk factors are associated with fatal or near-fatal anaphylaxis: adolescents and young adults are at particularly high risk, likely due to risk-taking behavior, reluctance to carry epinephrine, and eating away from home without supervision. Patients with both food allergy and asthma, especially poorly controlled asthma, are at significantly higher risk of fatal reactions. Delayed or absent epinephrine use is the single most consistent factor in fatal food allergy reactions. Peanuts and tree nuts are the allergens most commonly associated with fatal reactions, though any allergen can be involved. Other risk factors include previous severe reactions, reliance on antihistamines instead of epinephrine, and lack of an emergency action plan. Understanding these risk factors can help individuals and families take targeted steps to reduce their risk.
Reducing Your Risk of Fatal Anaphylaxis
While anaphylaxis cannot always be prevented, the risk of a fatal outcome can be significantly reduced through consistent, proactive measures. The most important step is to always carry two epinephrine auto-injectors. Studies of fatal food allergy reactions consistently show that the majority of victims either did not have epinephrine available or delayed its use. Carry your auto-injectors on your person (not in a car, locker, or purse that might not be with you) and check expiration dates regularly. Second, if you have asthma, keep it well-controlled. Take controller medications as prescribed and keep a rescue inhaler accessible. Third, develop and distribute a comprehensive anaphylaxis action plan and make sure everyone in your daily life knows where your epinephrine is and how to use it. Fourth, wear medical identification jewelry that lists your allergens and the fact that you carry epinephrine. In a situation where you cannot speak for yourself, this information can save your life. Fifth, avoid your allergen with consistent vigilance: read every label every time, communicate clearly at restaurants, and do not eat foods of unknown ingredients. Sixth, be cautious with cofactors: avoid exercising within several hours of eating if you have a history of food-dependent exercise-induced anaphylaxis, and be aware that alcohol and NSAIDs can lower your reaction threshold. Finally, see your allergist regularly to stay current on your allergy status, testing, and emerging treatment options.
Medical Disclaimer: This information is sourced from peer-reviewed medical literature and authoritative health organizations. It is for educational purposes only and should not replace advice from your healthcare provider. Always consult with a board-certified allergist about your specific condition.